<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553667</url>
  </required_header>
  <id_info>
    <org_study_id>201701797B0</org_study_id>
    <nct_id>NCT03553667</nct_id>
  </id_info>
  <brief_title>Using the &quot;Edwards&quot; EV1000 Clinical Platform NI in Lymphatic Venous Anastomosis</brief_title>
  <official_title>Perioperative Hemodynamic Optimization Using the &quot;Edwards&quot; EV1000 Clinical Platform NI in Lymphatic Venous Anastomosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymphatic venous anastomosis could be applied on patients suffering from limb lymphedema
      after surgery or radiotherapy. The particular pathophysiology leads unconventional fluid
      treatment strategy and changes in urine output. Hemodynamic monitors shows the benefits in
      perianesthetic care in fluid maintenance and decrease postanesthetic complication.

      Invasive hemodynamic monitors, such as arterial line and FlowTrac, have risks of hematoma,
      infection, nerve injury in puncture site. In this study, photoplethysmography is applied
      comparing with conventional mean arterial pressure for perianesthetic hemodynamic
      optimization in bispectral index (BIS)-guided target-controlled infusion sedation on
      lymphatic venous anastomosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After allocation, patients would be assigned to Standard group or ClearSight group. All
      patients will be sedative with BIS-guided Propofol/Alfentanil Target-Controlled Infusion. The
      BIS will be maintained between 40-70 with electromyography(EMG) &lt; 30%. Ce(effect site
      concentration) of Propofol is adjusted according to BIS score. Ce of Alfentanil is adjusted
      between 15-75 ng/ml. Patients have spontaneous respiration during the procedure with O2
      simple mask. If the oxygen saturation by pulse oximetry(SpO2) &lt; 95%, prescribe chin lift
      first. Nasopharyngeal airways is given if chin lift can not improve the saturation.
      Crystalloid, usually Lactate Ringer, is infused with the rate 4ml/kg/hr. The goal of Standard
      group is to maintain mean arterial pressure(MAP) &gt; 60%. If MAP &lt; 60%, 3ml/kg crystalloid is
      challenged in 10 minutes. If MAP still less than 60% after the second fluid challenge,
      Ephedrine 4-8mg iv is prescribed. ClearSight group is to maintain stroke volume(SV). If SV
      decreases more than 10%, 3ml/kg crystalloid is challenged in 10 minutes. If MAP still less
      than 60% after the second fluid challenge, Ephedrine 4-8mg iv is prescribed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal MAP fluctuation</measure>
    <time_frame>after induction until recovery from anesthesia, assessed up to 24 hours</time_frame>
    <description>In standard group, MAP(mean arterial pressure measured from arterial line), maximum minus minimum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal change of SVV</measure>
    <time_frame>after induction until recovery from anesthesia, assessed up to 24 hours</time_frame>
    <description>In ClearSight group, SVV(stroke volume variation measured from ClearSight), maximum minus minimum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>after induction until recovery from anesthesia, assessed up to 24 hours</time_frame>
    <description>urine output ml/kg/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>preanesthesia and 24 hours postanesthesia</time_frame>
    <description>Creatinine (serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Loss of kidney function that develops within 7 days after surgery</time_frame>
    <description>use AKIN/RIFLE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fluid volume (ml)</measure>
    <time_frame>after induction until recovery from anesthesia, assessed up to 24 hours</time_frame>
    <description>In both groups, total crystalloid fluid volume used during anesthesia</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fluid responsiveness</measure>
    <time_frame>after induction until recovery from anesthesia, assessed up to 24 hours</time_frame>
    <description>After fluid challenge, MAP changes in Standard group or SV changes in ClearSight group</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative adverse events</measure>
    <time_frame>postoperative 30 days</time_frame>
    <description>Including ileus, infection, and cardiovascular events</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>Postoperative nausea and vomiting</description>
  </other_outcome>
  <other_outcome>
    <measure>Recovery time</measure>
    <time_frame>From the stop of propofol infusion until full orientation of patient, up to 2 hours</time_frame>
    <description>From the stop of propofol infusion until full orientation of patient. Full orientation needs patients to be aware of where they are and who they are.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemodynamic Monitoring</condition>
  <condition>Perioperative Care</condition>
  <condition>Outcome Assessment</condition>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adult patients, Creatinine clearance &gt;= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ClearSight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients, Creatinine clearance &gt;= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard group</intervention_name>
    <description>Use radial arterial line to monitor mean arterial pressure</description>
    <arm_group_label>Standard group</arm_group_label>
    <other_name>S group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClearSight</intervention_name>
    <description>Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)</description>
    <arm_group_label>ClearSight</arm_group_label>
    <other_name>CS group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject receiving lymphatic venous anastomosis operation with Bispectral-guided
             Propofol and Alfentanil target-controlled anesthesia

          -  Subject agrees to participate the study

        Exclusion Criteria:

          -  Age less than 18 years old

          -  Creatinine clearance &lt; 30ml/min

          -  Vulnerable populations, including children, pregnant women, inmates, and persons with
             no capacity or with limited capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Chun Wu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Hsien Chiang, M.D.</last_name>
    <phone>+886-7-7317123</phone>
    <phone_ext>2788</phone_ext>
    <email>b9005035@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johnson Chia-Shen Yang, M.D.</last_name>
    <phone>+886-7-7317123</phone>
    <phone_ext>2788</phone_ext>
  </overall_contact_backup>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodynamic Monitoring</keyword>
  <keyword>Perioperative Care</keyword>
  <keyword>Outcome Assessment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

